Winclob-OC Cream is a topical formulation combining Ofloxacin (0.75% w/w), Ornidazole (2% w/w), Itraconazole (1% w/w), and Clobetasol (0.05% w/w) designed for the effective management of mixed bacterial, protozoal, fungal infections, and inflammatory dermatoses. Ofloxacin, a broad-spectrum fluoroquinolone antibiotic, targets gram-positive and gram-negative bacteria by inhibiting DNA gyrase, thereby preventing bacterial replication. Ornidazole, a nitroimidazole derivative, exhibits potent activity against anaerobic protozoa and bacteria by disrupting DNA synthesis. Itraconazole, a triazole antifungal agent, impedes ergosterol synthesis essential for fungal cell membrane integrity, effectively treating dermatophytic and yeast infections. Clobetasol propionate, a potent corticosteroid, provides anti-inflammatory, antipruritic, and vasoconstrictive effects, reducing erythema, swelling, and itching associated with inflammatory skin conditions. The synergistic combination in Winclob-OC Cream offers comprehensive treatment for complex dermatological infections where mixed microbial flora and inflammation coexist. It is indicated for conditions such as infected eczema, dermatitis, fungal-bacterial co-infections, and other inflammatory dermatoses with secondary microbial involvement. Application should follow medical advice, avoiding prolonged use to minimize potential corticosteroid-related adverse effects such as skin atrophy or systemic absorption. Winclob-OC Cream should not be used in viral infections or hypersensitivity to any component.